Quarterly Period Covered: Second quarter of fiscal year 2026 (July 1 - December 31, 2025), filed February 3, 2026 Financial Statements and Disclosures: Contains consolidated balance sheets, income statements, cash flow statements, and detailed notes covering the six-month period ended December 31, 2025, compared to prior year periods Derivative Instruments and Risk Management: Includes extensive…

Our analysis rates this filing NEUTRAL. Clorox presents a balanced risk profile appropriate for a stable, mature consumer staples company. The concern level of 5.2 reflects two material but manageable ongoing issues: (1) contingent consideration obligations from the Glad business investment with…

Concern level: ELEVATED (5.2/10). Key factors: Contingent consideration obligations related to Glad business investment remain unresolved with Q1 2026 forecast scenarios indicating ongoing earn-out or payment obligations; August 2023 cyberattack costs continue to be separately tracked 18+ months post-incident, suggesting extended remediation timeline or unresolved litigation/settlement…

Notable risk changes: Glad Business contingent consideration remains active with specific Q1 2026 forecast scenarios disclosed, indicating unresolved earn-out or contingent payment obligations; August 2023 cyberattack costs continue to be separately tracked in non-operating expenses 18+ months post-incident, suggesting extended remediation period or ongoing litigation; Vitamins, Minerals and Supplements business…

The model predicts CLX will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.